

Molecular cancer therapeutics

Nonclinical efficacy and safety of CX-2029, an anti-CD71 probody–drug conjugate

View Publication

Details

Authors:

Shweta Singhal, Olga Vasiljeva, et al.

Title of the Article:

Nonclinical efficacy and safety of CX-2029, an anti-CD71 probody–drug conjugate

Journal:

Molecular cancer therapeutics

Year of Publication:

2022

Pages:

1326-1-1336

Volume and Issue Number:

vol. 21, no. 8

ISSN Number:

1538-8514

DOI (Digital Object Identifier):

10.1158/1535-7163.MCT-21-0193

COBISS ID:

116988419

Researchers

Researchers

Meet our dedicated researchers behind this publication:

Olga Vasiljeva

References

References & Citations

More documentation

Related publications

Browse all publications

Journal of Experimental Biology

In vivo continuous three-dimensional magnetic resonance microscopy: a study of metamorphosis in Carniolan worker honey bees (Apis mellifera carnica)

MOHORIČ, Aleš, BOŽIČ, Janko, MRAK, Polona, TUŠAR, Kaja, CHENYUN, Lin, SEPE, Ana, MIKAC, Urška, MIKHAYLOV, Georgy, SERŠA, Igor

10.1242/jeb.225250

International journal of molecular sciences

The structure of clostridioides difficile SecA2 atpase exposes regions responsible for differential target recognition of the SecA1 and SecA2-dependent systems

LINDIČ, Nataša, LOBODA, Jure, USENIK, Aleksandra, VIDMAR, Robert, TURK, Dušan

10.3390/ijms21249413

International journal of molecular sciences

Time-dependent miRNA frofile during septic acute kidney injury in mice

TOD, Pál, RÓKA, Beáta, KAUCSÁR, Tamás, SZATMÁRI, Krisztina, VIZOVIŠEK, Matej, VIDMAR, Robert, FONOVIĆ, Marko, SZÉNÁSI, Gábor, HAMAR, Péter

10.3390/ijms21155316

Explore our collection of 200+ Premium Webflow Templates